AB0474 Changes in T and B Lymphocyte Subsets with Tofacitinib do not Translate from Nonclinical Species to Humans

• Published in: Annals of the rheumatic diseases Vol. 73; no. Suppl 2; pp. 964 - 965
• Main Authors: Ball, D.J., Kawabata, T.T., Vogel, W.M., Riese, R.J., Krishnaswami, S., Lamba, M., Brown, M.J., Zwillich, S.H.
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Limited 01.06.2014

Background Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines involved in lymphocyte development, function and homeostasis (e.g., interleukin (IL)-2, -4, -7, -15, -21) signal through JAK. Repeat dose toxicology studies were conducted in rats...